Inclusion Criteria:  Age ≥ 18 years Infection with SARS-CoV-2 (virus detection by means of a PCR test not older than 72 hours) Bipulmonary infiltrates (detection by means of X-rays or computed tomography) COVID inflammation score ≥ 10 Ferritin concentration (serum or plasma) ≥ 500 ng / ml Arterial oxygen saturation ≤ 93% when breathing room air written informed consent from the patient Potentially childbearing women: negative pregnancy test  Exclusion Criteria (in medical history):  Contraindications study medication:  Hypersensitivity to the active substance infliximab (or any of the other ingredients of the medicine) or to other murine proteins active or latent tuberculosis acute or chronic hepatitis B severe infections such as invasive fungal infections, bacterial sepsis, or abscesses opportunistic infections (e.g. pneumocystosis, listeriosis) moderate or severe heart failure (NYHA class III / IV) Immunosuppression (e.g. organ transplantation, AIDS, leukopenia) Malignancies or lymphoproliferative diseases or chemotherapy within the last 4 weeks Multiple sclerosis or peripheral demyelinating diseases, including the Guillain-Barré syndrome Treatment with other biologics for therapy for approved indications of infliximab (e.g. for rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, psoriasis)  Further exclusion criteria:  Autoimmune disease with biologics therapy Current treatment with TNF antibodies, convalescent plasma, bamlanivimab, or other experimental treatments for COVID-19 High-flow oxygen therapy, non-invasive / invasive ventilation (WHO-COVID-19 PROGRESSION Scale > 5) pre-existing long-term ventilation or home oxygen therapy Child-Pugh C liver cirrhosis Pregnancy or breastfeeding Patients with a life expectancy < 90 days due to other medical conditions Limitation or discontinuation of therapy (e.g. refusal of artificial ventilation) Participation in another interventional study Previous participation in this study Interdependence between the patient and the coordinating investigator or other members of the study team